UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Unicycive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.51+0.15 (+4.46%)
Close on Oct 19, 2026
- Market cap
- $94.48M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.20 (−25.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $94.48M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.77
- Dividend yield
- –
- Free cash flow yield
- -29.48%
Fundamentals
- Net income
- -$35.22M
- EPS, diluted
- -$1.67
- Free cash flow
- -$27.85M
- Book value per share
- $1.98
- Diluted shares
- 27M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$33.14M
Net income
-$35.22M
EPS, diluted
–
Free cash flow
-$27.85M
Reported periodTrailing twelve months